[go: up one dir, main page]

MX2014001023A - Derivados de quinazolina. - Google Patents

Derivados de quinazolina.

Info

Publication number
MX2014001023A
MX2014001023A MX2014001023A MX2014001023A MX2014001023A MX 2014001023 A MX2014001023 A MX 2014001023A MX 2014001023 A MX2014001023 A MX 2014001023A MX 2014001023 A MX2014001023 A MX 2014001023A MX 2014001023 A MX2014001023 A MX 2014001023A
Authority
MX
Mexico
Prior art keywords
quinazoline derivatives
quinazoline
angiogenesis
derivatives
treating
Prior art date
Application number
MX2014001023A
Other languages
English (en)
Other versions
MX340021B (es
Inventor
Wei-Guo Su
Weihan Zhang
Xiaoqiang Yan
Yumin Cui
Yongxin Ren
Jifeng Duan
Original Assignee
Hutchison Medipharma Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Entpr Ltd filed Critical Hutchison Medipharma Entpr Ltd
Publication of MX2014001023A publication Critical patent/MX2014001023A/es
Publication of MX340021B publication Critical patent/MX340021B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de quinazolina que tienen un sustituyente de benzofurano. También se divulga un método para tratar un desorden relacionado con la angiogénesis con uno de estos compuestos.
MX2014001023A 2008-05-09 2009-05-08 Derivados de quinazolina. MX340021B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/118,019 US7829574B2 (en) 2008-05-09 2008-05-09 Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
PCT/US2009/043347 WO2009137797A2 (en) 2008-05-09 2009-05-08 Quinazoline derivatives

Publications (2)

Publication Number Publication Date
MX2014001023A true MX2014001023A (es) 2014-05-22
MX340021B MX340021B (es) 2016-06-22

Family

ID=41265455

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014001023A MX340021B (es) 2008-05-09 2009-05-08 Derivados de quinazolina.
MX2010012168A MX2010012168A (es) 2008-05-09 2009-05-08 Derivados de quinazolina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010012168A MX2010012168A (es) 2008-05-09 2009-05-08 Derivados de quinazolina.

Country Status (22)

Country Link
US (3) US7829574B2 (es)
EP (1) EP2297115B1 (es)
JP (2) JP5856842B2 (es)
KR (2) KR101686679B1 (es)
AU (1) AU2009244130B2 (es)
BR (1) BRPI0908675B1 (es)
CA (1) CA2723148C (es)
CY (1) CY1117222T1 (es)
DK (1) DK2297115T3 (es)
ES (1) ES2550245T3 (es)
HR (1) HRP20150954T1 (es)
HU (1) HUE025723T2 (es)
MX (2) MX340021B (es)
MY (1) MY155566A (es)
NZ (1) NZ588900A (es)
PH (1) PH12013500363A1 (es)
PL (1) PL2297115T3 (es)
PT (1) PT2297115E (es)
RU (1) RU2506261C2 (es)
SI (1) SI2297115T1 (es)
TW (1) TWI458724B (es)
WO (1) WO2009137797A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
KR101699991B1 (ko) * 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
LT3575288T (lt) 2009-09-03 2021-12-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
US11016085B2 (en) 2016-04-25 2021-05-25 The Johns Hopkins University ZNT8 assays for drug development and pharmaceutical compositions
WO2019014044A1 (en) 2017-07-12 2019-01-17 The Johns Hopkins University ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES
CN116987069B (zh) * 2018-03-30 2025-12-02 杭州领业医药科技有限公司 呋喹替尼的共晶、其制备方法、组合物和用途
US12103968B2 (en) 2018-08-16 2024-10-01 The Johns Hopkins University Antibodies to human ZnT8
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
CN110898065A (zh) * 2019-11-25 2020-03-24 南通大学 呋喹替尼或其盐在制备治疗脉络膜新生血管药物中的用途
MX2023012060A (es) 2021-04-13 2024-01-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
PL205557B1 (pl) * 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
DE10009267A1 (de) * 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2002030926A1 (en) * 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives
US6849625B2 (en) * 2000-10-13 2005-02-01 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
WO2002070477A1 (en) 2001-03-01 2002-09-12 Ono Pharmaceutical Co., Ltd. 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor
AU2002347336A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
AU2004255581A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
GEP20084572B (en) 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
WO2005097134A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
US20070299092A1 (en) 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
WO2005114219A2 (en) * 2004-05-20 2005-12-01 Wyeth Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
CA2612227C (en) 2005-06-14 2014-04-22 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EP1963310A2 (en) 2005-12-05 2008-09-03 Pfizer Products Incorporated Methods of preparing a vegf-r inhibitor
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
AU2007249762A1 (en) 2006-05-15 2007-11-22 Senex Biotechnology, Inc Identification of CDKI pathway inhibitors
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

Also Published As

Publication number Publication date
ES2550245T3 (es) 2015-11-05
US20110015213A1 (en) 2011-01-20
US8212033B2 (en) 2012-07-03
NZ588900A (en) 2012-12-21
US8497372B2 (en) 2013-07-30
WO2009137797A2 (en) 2009-11-12
HUE025723T2 (en) 2016-04-28
JP2011519956A (ja) 2011-07-14
KR20160045925A (ko) 2016-04-27
RU2506261C2 (ru) 2014-02-10
CA2723148A1 (en) 2009-11-12
CY1117222T1 (el) 2017-04-05
KR101686679B1 (ko) 2016-12-14
AU2009244130A1 (en) 2009-11-12
PH12013500363A1 (en) 2013-09-02
US20090281130A1 (en) 2009-11-12
EP2297115A2 (en) 2011-03-23
MX340021B (es) 2016-06-22
TWI458724B (zh) 2014-11-01
TW201002694A (en) 2010-01-16
AU2009244130B2 (en) 2012-11-01
MX2010012168A (es) 2011-02-18
EP2297115A4 (en) 2012-03-14
RU2010150345A (ru) 2012-06-20
PT2297115E (pt) 2015-10-26
SI2297115T1 (sl) 2015-10-30
US7829574B2 (en) 2010-11-09
CA2723148C (en) 2015-01-20
BRPI0908675B1 (pt) 2022-01-25
US20120238572A1 (en) 2012-09-20
EP2297115B1 (en) 2015-07-22
HRP20150954T1 (hr) 2015-10-09
JP2014177499A (ja) 2014-09-25
WO2009137797A3 (en) 2010-02-25
PL2297115T3 (pl) 2015-12-31
BRPI0908675A2 (pt) 2015-08-04
KR20110013381A (ko) 2011-02-09
MY155566A (en) 2015-10-30
DK2297115T3 (en) 2015-08-10
JP5856842B2 (ja) 2016-02-10

Similar Documents

Publication Publication Date Title
MX2014001023A (es) Derivados de quinazolina.
MY150493A (en) Quinazoline derivatives
ATE533485T1 (de) Cetp-inhibitoren
UA115026C2 (uk) Похідні гетероарилпіперидину та -піперазину як фунгіциди
TW200745138A (en) Process for stabilising thiophene derivatives
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
TW200942533A (en) Pyridyl inhibitors of hedgehog signalling
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
MX2009009290A (es) Compuestos activos en ppar.
MX2009011199A (es) Derivados de pirimidina.
TW200621230A (en) Anti-tumor compounds
MX2012008141A (es) Compuestos y metodos.
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
MX2010005557A (es) Derivados de indolinona y procedimiento para su fabricacion.
NZ579928A (en) Fluorinated derivatives of deferiprone
TW200745028A (en) Novel sulphonylpyrroles
MX2013008560A (es) Metodo para preparar derivados de 2-aminobenzamida.
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
MY178390A (en) Inhibitors of iap
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
SG196785A1 (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4, 3-c] isoquinoline derivatives
TW200745027A (en) Novel sulphonylpyrroles
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.

Legal Events

Date Code Title Description
FG Grant or registration